Company intelligence / Profile preview
Bod Science Limited
Sydney, New South Wales, Australiabodscience.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Bod Science Limited develops cannabinoid-based therapeutics with a focus on scientifically validated clinical trials. The company has completed a Phase IIb trial of its CBD formulation for insomnia and has launched MediCabilis™ CBG50 after positive proof-of-concept results in fibromyalgia and IBD. It also runs trials targeting long COVID symptoms. Its products are available by prescription in Australia and the UK.
- Therapeutic areas
- GastroenterologyPsychiatryDermatologyNeurologyInfectious Diseases
- Modalities
- Cannabinoids (CBD, CBG)Cannabis extractsHerbal products
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Collaborations with leading research organisations such as Drug Science UKWoolcock Institute of Medical Research conducted the Phase IIb insomnia trial.
Beyond the preview
Go deeper on Bod Science Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bod Science Limited.